Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, Ma...
24 Février 2015 - 10:00PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will
host a webcast and conference call to discuss the Company's
financial results for the quarter and year ended December 31, 2014,
and provide a general business overview on Monday, March 2, 2015,
at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (877) 280-4958
from the U.S. and Canada or +1(857) 244-7315 internationally, and
use the passcode 71124473. Please dial in 10 minutes prior to the
start of the call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
company's website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary. A replay of the
webcast will be available on the Company's website for 30 days
following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing its three wholly-owned programs using novel biomarker and
genetic approaches that may increase the likelihood of clinical,
regulatory and commercial success of its potentially life-saving
therapies. Portola's partnered program is focused on developing
selective Syk inhibitors for inflammatory conditions.
Betrixaban
Portola's wholly-owned, oral, once-daily Factor Xa inhibitor
betrixaban is being evaluated in the only biomarker-based Phase 3
study for hospital-to-home prophylaxis of venous thromboembolism
(VTE) in acute medically ill patients. Betrixaban's distinct
properties may have the potential to allow the agent to demonstrate
efficacy without the significant increase in the rate of major
bleeding that was seen in this patient population with other Factor
Xa inhibitors. If approved, betrixaban could be the first
anticoagulant for both hospital and post-discharge VTE prophylaxis
and the standard of care in this large market of more than 20
million patients in the G7 countries alone.
Andexanet Alfa
Andexanet alfa, a U.S. Food and Drug Administration
(FDA)-designated breakthrough therapy, is a recombinant protein
designed to reverse the anticoagulant activity in patients treated
with an oral or injectable Factor Xa inhibitor. Andexanet alfa has
the potential to be a first-in-class antidote for anticoagulated
patients who suffer a major bleeding episode or require emergency
surgery. Portola has entered into Phase 3 clinical collaboration
agreements with all of the manufacturers of direct Factor Xa
inhibitors – Bristol-Myers Squibb and Pfizer (Eliquis
[apixaban]), Bayer HealthCare and Janssen Pharmaceuticals (XARELTO®
[rivaroxaban]), and Daiichi Sankyo (edoxaban) – while retaining all
commercial rights to andexanet alfa. The Company is currently
evaluating andexanet alfa in the Phase 3 and Phase 4 ANNEXA™
(Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of
fXA Inhibitors) registration studies.
Cerdulatinib
Portola's product candidate in the area of hematologic cancer,
cerdulatinib, is an orally available molecule that uniquely
inhibits two validated tumor proliferation pathways – spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
evaluated in a Phase 1/2a proof-of-concept study in patients with B
cell leukemias or lymphomas with a focus on genetically-defined
subtypes, as well as in patients who have failed therapy due to
relapse or acquired mutations.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
CONTACT: Portola
Media:
Joey Fleury, BrewLife,
jfleury@brewlife.com, 415.946.1090
Investors:
Alexandra Santos, Portola Pharmaceuticals,
ir@portola.com, 650.246.7239
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024